Regulus Receives Final Milestone Payment From Biogen For Multiple Sclerosis Development

Today Regulus Therapeutics (RGLS) announced that it has received its fourth and final milestone payment from Biogen (BIIB).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.